Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: Identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs

Kyle Johnson, Li Liu, Nazanin Majdzadeh, Cindy Chavez, Paul C. Chin, Brad Morrison, Lulu Wang, Jane Park, Priti Chugh, Hsin Mei Chen, Santosh R. D'Mello

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Increasing evidence suggests that neuronal apoptosis is triggered by the inappropriate activation of cyclin-dependent kinases leading to an abortive re-entry of neurons into the cell cycle. Pharmacological inhibitors of cell-cycle progression may therefore have value in the treatment of neurodegenerative diseases in humans. GW8510 is a 3′ substituted indolone that was developed recently as an inhibitor of cyclin-dependent kinase 2 (CDK2). We found that GW8510 inhibits the death of cerebellar granule neurons caused by switching them from high potassium (HK) medium to low potassium (LK) medium. Although GW8510 inhibits CDK2 and other CDKs when tested in in vitro biochemical assays, when used on cultured neurons it only inhibits CDK5, a cytoplasmic CDK that is not associated with cell-cycle progression. Treatment of cultured HEK293T cells with GW8510 does not inhibit cell-cycle progression, consistent with its inability to inhibit mitotic CDKs in intact cells. Neuroprotection by GW8510 is independent of Akt and MEK-ERK signaling. Furthermore, GW8510 does not block the LK-induced activation of Gsk3β and, while inhibiting c-jun phosphorylation, does not inhibit the increase in c-jun expression observed in apoptotic neurons. We also examined the effectiveness of other 3′ substituted indolone compounds to protect against neuronal apoptosis. We found that like GW8510, the VEGF Receptor 2 Kinase Inhibitors [3-(1H-pyrrol-2- ylmethylene)-1,3-dihydroindol-2-one], {(Z)-3-[2,4-Dimethyl-3-(ethoxycarbonyl) pyrrol-5-yl)methylidenyl]indol-2-one} and [(Z)-5-Bromo-3-(4,5,6,6-tetrahydro-1H- indol-2-ylmethylene)-1,3-dihydroindol-2-one], the Src family kinase inhibitor SU6656 and a commercially available inactive structural analog of an RNA-dependent protein kinase inhibitor 5-Chloro-3-(3,5-dichloro-4- hydroxybenzylidene)-1,3-dihydro-indol-2-one, are all neuroprotective when tested on LK-treated neurons. Along with our recent identification of the c-Raf inhibitor GW5074 (also a 3′ substituted indolone) as a neuroprotective compound, ourfindings identify the 3′ substituted indolone as a core structure for the designing of neuroprotective drugs that may be used to treat neurodegenerative diseases in humans.

Original languageEnglish (US)
Pages (from-to)538-548
Number of pages11
JournalJournal of Neurochemistry
Volume93
Issue number3
DOIs
StatePublished - May 2005

Fingerprint

Cyclin-Dependent Kinases
Neuroprotective Agents
Scaffolds
Apoptosis
Neurons
Cell Cycle
Cells
Cyclin-Dependent Kinase 2
Neurodegenerative diseases
Neurodegenerative Diseases
Potassium
Chemical activation
eIF-2 Kinase
Phosphorylation
Vascular Endothelial Growth Factor Receptor
src-Family Kinases
Reentry
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors
GW8510

Keywords

  • 3′ substituted indolones
  • Cerebellar granule neurons
  • Cyclin-dependent kinases
  • Neurodegeneration
  • Neuronal apoptosis
  • Neuroprotection

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510 : Identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs. / Johnson, Kyle; Liu, Li; Majdzadeh, Nazanin; Chavez, Cindy; Chin, Paul C.; Morrison, Brad; Wang, Lulu; Park, Jane; Chugh, Priti; Chen, Hsin Mei; D'Mello, Santosh R.

In: Journal of Neurochemistry, Vol. 93, No. 3, 05.2005, p. 538-548.

Research output: Contribution to journalArticle

Johnson, Kyle ; Liu, Li ; Majdzadeh, Nazanin ; Chavez, Cindy ; Chin, Paul C. ; Morrison, Brad ; Wang, Lulu ; Park, Jane ; Chugh, Priti ; Chen, Hsin Mei ; D'Mello, Santosh R. / Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510 : Identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs. In: Journal of Neurochemistry. 2005 ; Vol. 93, No. 3. pp. 538-548.
@article{0a187fe420da4db5b298d804b1c84c22,
title = "Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: Identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs",
abstract = "Increasing evidence suggests that neuronal apoptosis is triggered by the inappropriate activation of cyclin-dependent kinases leading to an abortive re-entry of neurons into the cell cycle. Pharmacological inhibitors of cell-cycle progression may therefore have value in the treatment of neurodegenerative diseases in humans. GW8510 is a 3′ substituted indolone that was developed recently as an inhibitor of cyclin-dependent kinase 2 (CDK2). We found that GW8510 inhibits the death of cerebellar granule neurons caused by switching them from high potassium (HK) medium to low potassium (LK) medium. Although GW8510 inhibits CDK2 and other CDKs when tested in in vitro biochemical assays, when used on cultured neurons it only inhibits CDK5, a cytoplasmic CDK that is not associated with cell-cycle progression. Treatment of cultured HEK293T cells with GW8510 does not inhibit cell-cycle progression, consistent with its inability to inhibit mitotic CDKs in intact cells. Neuroprotection by GW8510 is independent of Akt and MEK-ERK signaling. Furthermore, GW8510 does not block the LK-induced activation of Gsk3β and, while inhibiting c-jun phosphorylation, does not inhibit the increase in c-jun expression observed in apoptotic neurons. We also examined the effectiveness of other 3′ substituted indolone compounds to protect against neuronal apoptosis. We found that like GW8510, the VEGF Receptor 2 Kinase Inhibitors [3-(1H-pyrrol-2- ylmethylene)-1,3-dihydroindol-2-one], {(Z)-3-[2,4-Dimethyl-3-(ethoxycarbonyl) pyrrol-5-yl)methylidenyl]indol-2-one} and [(Z)-5-Bromo-3-(4,5,6,6-tetrahydro-1H- indol-2-ylmethylene)-1,3-dihydroindol-2-one], the Src family kinase inhibitor SU6656 and a commercially available inactive structural analog of an RNA-dependent protein kinase inhibitor 5-Chloro-3-(3,5-dichloro-4- hydroxybenzylidene)-1,3-dihydro-indol-2-one, are all neuroprotective when tested on LK-treated neurons. Along with our recent identification of the c-Raf inhibitor GW5074 (also a 3′ substituted indolone) as a neuroprotective compound, ourfindings identify the 3′ substituted indolone as a core structure for the designing of neuroprotective drugs that may be used to treat neurodegenerative diseases in humans.",
keywords = "3′ substituted indolones, Cerebellar granule neurons, Cyclin-dependent kinases, Neurodegeneration, Neuronal apoptosis, Neuroprotection",
author = "Kyle Johnson and Li Liu and Nazanin Majdzadeh and Cindy Chavez and Chin, {Paul C.} and Brad Morrison and Lulu Wang and Jane Park and Priti Chugh and Chen, {Hsin Mei} and D'Mello, {Santosh R.}",
year = "2005",
month = "5",
doi = "10.1111/j.1471-4159.2004.03004.x",
language = "English (US)",
volume = "93",
pages = "538--548",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510

T2 - Identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs

AU - Johnson, Kyle

AU - Liu, Li

AU - Majdzadeh, Nazanin

AU - Chavez, Cindy

AU - Chin, Paul C.

AU - Morrison, Brad

AU - Wang, Lulu

AU - Park, Jane

AU - Chugh, Priti

AU - Chen, Hsin Mei

AU - D'Mello, Santosh R.

PY - 2005/5

Y1 - 2005/5

N2 - Increasing evidence suggests that neuronal apoptosis is triggered by the inappropriate activation of cyclin-dependent kinases leading to an abortive re-entry of neurons into the cell cycle. Pharmacological inhibitors of cell-cycle progression may therefore have value in the treatment of neurodegenerative diseases in humans. GW8510 is a 3′ substituted indolone that was developed recently as an inhibitor of cyclin-dependent kinase 2 (CDK2). We found that GW8510 inhibits the death of cerebellar granule neurons caused by switching them from high potassium (HK) medium to low potassium (LK) medium. Although GW8510 inhibits CDK2 and other CDKs when tested in in vitro biochemical assays, when used on cultured neurons it only inhibits CDK5, a cytoplasmic CDK that is not associated with cell-cycle progression. Treatment of cultured HEK293T cells with GW8510 does not inhibit cell-cycle progression, consistent with its inability to inhibit mitotic CDKs in intact cells. Neuroprotection by GW8510 is independent of Akt and MEK-ERK signaling. Furthermore, GW8510 does not block the LK-induced activation of Gsk3β and, while inhibiting c-jun phosphorylation, does not inhibit the increase in c-jun expression observed in apoptotic neurons. We also examined the effectiveness of other 3′ substituted indolone compounds to protect against neuronal apoptosis. We found that like GW8510, the VEGF Receptor 2 Kinase Inhibitors [3-(1H-pyrrol-2- ylmethylene)-1,3-dihydroindol-2-one], {(Z)-3-[2,4-Dimethyl-3-(ethoxycarbonyl) pyrrol-5-yl)methylidenyl]indol-2-one} and [(Z)-5-Bromo-3-(4,5,6,6-tetrahydro-1H- indol-2-ylmethylene)-1,3-dihydroindol-2-one], the Src family kinase inhibitor SU6656 and a commercially available inactive structural analog of an RNA-dependent protein kinase inhibitor 5-Chloro-3-(3,5-dichloro-4- hydroxybenzylidene)-1,3-dihydro-indol-2-one, are all neuroprotective when tested on LK-treated neurons. Along with our recent identification of the c-Raf inhibitor GW5074 (also a 3′ substituted indolone) as a neuroprotective compound, ourfindings identify the 3′ substituted indolone as a core structure for the designing of neuroprotective drugs that may be used to treat neurodegenerative diseases in humans.

AB - Increasing evidence suggests that neuronal apoptosis is triggered by the inappropriate activation of cyclin-dependent kinases leading to an abortive re-entry of neurons into the cell cycle. Pharmacological inhibitors of cell-cycle progression may therefore have value in the treatment of neurodegenerative diseases in humans. GW8510 is a 3′ substituted indolone that was developed recently as an inhibitor of cyclin-dependent kinase 2 (CDK2). We found that GW8510 inhibits the death of cerebellar granule neurons caused by switching them from high potassium (HK) medium to low potassium (LK) medium. Although GW8510 inhibits CDK2 and other CDKs when tested in in vitro biochemical assays, when used on cultured neurons it only inhibits CDK5, a cytoplasmic CDK that is not associated with cell-cycle progression. Treatment of cultured HEK293T cells with GW8510 does not inhibit cell-cycle progression, consistent with its inability to inhibit mitotic CDKs in intact cells. Neuroprotection by GW8510 is independent of Akt and MEK-ERK signaling. Furthermore, GW8510 does not block the LK-induced activation of Gsk3β and, while inhibiting c-jun phosphorylation, does not inhibit the increase in c-jun expression observed in apoptotic neurons. We also examined the effectiveness of other 3′ substituted indolone compounds to protect against neuronal apoptosis. We found that like GW8510, the VEGF Receptor 2 Kinase Inhibitors [3-(1H-pyrrol-2- ylmethylene)-1,3-dihydroindol-2-one], {(Z)-3-[2,4-Dimethyl-3-(ethoxycarbonyl) pyrrol-5-yl)methylidenyl]indol-2-one} and [(Z)-5-Bromo-3-(4,5,6,6-tetrahydro-1H- indol-2-ylmethylene)-1,3-dihydroindol-2-one], the Src family kinase inhibitor SU6656 and a commercially available inactive structural analog of an RNA-dependent protein kinase inhibitor 5-Chloro-3-(3,5-dichloro-4- hydroxybenzylidene)-1,3-dihydro-indol-2-one, are all neuroprotective when tested on LK-treated neurons. Along with our recent identification of the c-Raf inhibitor GW5074 (also a 3′ substituted indolone) as a neuroprotective compound, ourfindings identify the 3′ substituted indolone as a core structure for the designing of neuroprotective drugs that may be used to treat neurodegenerative diseases in humans.

KW - 3′ substituted indolones

KW - Cerebellar granule neurons

KW - Cyclin-dependent kinases

KW - Neurodegeneration

KW - Neuronal apoptosis

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=20944431614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944431614&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2004.03004.x

DO - 10.1111/j.1471-4159.2004.03004.x

M3 - Article

C2 - 15836613

AN - SCOPUS:20944431614

VL - 93

SP - 538

EP - 548

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 3

ER -